FOLLOWING RELEASE OF FYE2025 RESULTS AND SECURING OF CLINICAL TRIAL INSURANCE POLICY, MAXIM GROUP REITERATES ITS BUY RECOMMENDATION ON AB SCIENCE’S STOCK WITH A TARGET PRICE OF EUR 4.0 PER SHARE Paris ...
AB SCIENCE PRESENTS ITS ANNUAL FINANCIAL RESULTS AS OF 31 DECEMBER 2025 AND KEY EVENTS FOR THE PERIOD Paris, 13 May 2025, 7pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces its ...
While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are ...
This new US patent adds to the IP coverage already granted in Europe (EP4175639). Counterpart patent applications have also been filed in other major international markets. Masitinib positioning in ...
AB Science SA (Euronext - FR0010557264 - AB) today announced that it has filed an application for conditional Marketing Authorization to the European Medicines Agency (EMA) for Alsitek (masitinib) in ...
The average one-year price target for AB Science (ENXTPA:AB) has been revised to €4.31 / share. This is an increase of 22.25% from the prior estimate of €3.53 dated September 27, 2025. The price ...
STONEGATE CAPITAL PARTNERS UPDATES ITS COVERAGE OF AB SCIENCE’S STOCK WITH A DISCOUNTED CASH FLOW VALUATION MID-POINT OF EUR 4.25 PER SHARE AB Science SA (Euronext - FR0010557264 - AB) announces that ...
AB Science S.A. Annual stock financials by MarketWatch. View the latest AB financial statements, income statements and financial ratios.
i) Approval by several European countries to initiate the confirmatory Phase 3 trial AB Science announced in July 2025 that the confirmatory Phase 3 trial with masitinib in amyotrophic lateral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results